Breaking News

Quotient Sciences Invests in Sterile Fill/Finish Capacity

Increases current capacity of the Annex 1 compliant facility to meet increasing industry demand for fully integrated drug development programs.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Drug development and manufacturing company Quotient Sciences has made a major investment in the sterile fill/finish capabilities at its Alnwick, UK facility. This investment will increase the current capacity of the Annex 1 compliant facility to meet increasing industry demand for fully integrated drug development programs. The company has state-of-the-art contract development and manufacturing (CDMO) facilities in both the U.S. and UK, which are fully integrated with their clinical testing f...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters